AEGiS-Glasgow [PL1.1] Clinical use of various HIV treatments

Eighth International Congress on Drug Therapy in HIV Infection

Glasgow, UK - 12-16 November 2006

[PL1.1] Clinical use of various HIV treatments

Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL1.1

Manuel Battegay
Universittspital, Basel, Switzerland

PURPOSE OF THE STUDY: Potent antiretroviral therapy (ART) has dramatically and increasingly reduced long-term morbidity and mortality since the mid-1990s. With the advent of many new drugs in recent years, multiple options have become available for initiating ART. Regimen design considerations include efficacy, durability, tolerability and long-term adverse effects, convenience, and drug-interactions, as well as the potential for salvaging the initial regimen (IAS USA and DHHS guidelines). Clinical use of various HIV treatments for the choice of initial therapy will be addressed in the light of newer approved drugs. Various treatments relate to preferred and alternative regimens, e.g. different NRTI backbones, PI-boosted versus NNRTI based regimens, and OD versus BID ART. Briefly, important aspects of various HIV treatments and patient characteristics, as well as co-morbidities (intravenous drug users, cardiovascular morbidity, pregnancy, HCV), will be reviewed for their clinical implications.

Plenary Session: Treatment Strategies

2006-11-12
PL1.1

Copyright © 2006 - Thomson ACUMED® All rights reserved. Thomson ACUMED® is an intelligent and innovative medical marketing and communications agency – a new division of The Gardiner-Caldwell Group Ltd, part of The Thomson Corporation, located in Tytherington, UK.

Reproduction of this abstract (other than one copy for personal reference) must be cleared through the authors.